Seroatlas · Human Serome Atlas

NACA2

Nascent polypeptide-associated complex subunit alpha-2

Also known as: MGC71999, NACA2_HUMAN, NACAL

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9H009
Gene: NACA2
Ensembl: ENSG00000253506
Chromosome: 17
Canonical length: 215 aa
Protein class: Predicted intracellular proteins
Subcellular location: Cytosol

OverviewNCBI Gene

Predicted to enable unfolded protein binding activity. Predicted to be involved in protein targeting to membrane. Predicted to be located in nucleus. Predicted to be part of nascent polypeptide-associated complex. Predicted to be active in cytoplasm. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

215 residues, UniProt reviewed canonical sequence.

>Q9H009|NACA2
     1  MPGEATETVP ATEQELPQSQ AETGSGTASD SGESVPGIEE QDSTQTTTQK AWLVAAAEID
    61  EEPVGKAKQS RSEKRARKAM SKLGLLQVTG VTRVTIWKSK NILFVITKLD VYKSPASDAY
   121  IVFGEAKIQD LSQQAQLAAA EKFRVQGEAV GNIQENTQTP TVQEESEEEE VDETGVEVKD
   181  VKLVMSQANV SRAKAVRALK NNSNDIVNAI MELTV

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against NACA2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.54
Highest tissue expression: 60 nTPM

Expression across tissuesHPA

Tissue

testis: 60 nTPM
ovary: 2 nTPM
skin: 1.4 nTPM
breast: 1.1 nTPM
esophagus: 1.1 nTPM
pancreas: 1.1 nTPM

Single-cell type

late primary spermatocytes: 658 nCPM
early spermatids: 371 nCPM
late spermatids: 168 nCPM
early primary spermatocytes: 26 nCPM
esophageal apical cells: 14 nCPM
papillary tip epithelial cells: 13 nCPM

Immune cell

total PBMC: 0.8 nTPM
intermediate monocyte: 0.7 nTPM
non-classical monocyte: 0.7 nTPM
memory B-cell: 0.4 nTPM
myeloid DC: 0.4 nTPM
naive B-cell: 0.4 nTPM

Brain region

basal ganglia: 0.1 nTPM
amygdala: 0 nTPM
cerebellum: 0 nTPM
cerebral cortex: 0 nTPM
choroid plexus: 0 nTPM
hippocampal formation: 0 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.82
gnomAD pLI: 0.03
gnomAD missense Z: 0
DepMap mean gene effect: -0.39
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

unfolded protein binding

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of NACA2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads NACA2 as an antibody target. Whether an autoantibody or antibody against NACA2 could matter depends on whether native NACA2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

NACA2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label NACA2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...